Metformin is a commonly used drug for the clinical treatment of T2DM, which improves the sensitivity and utilization of insulin in body tissues and reduces the occurrence of adverse events such as hypoglycemia and obesity (Pernicova and Korbonits, 2014). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.